[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356807-105":59,"doc-detail-356807-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","electronic-symptom-monitoring-of-patient-reported-outcomes-among-patients-with-hepatocellular-carcinoma-during-immunotherapy-prime-hcc-protocol-for-a-randomised-controlled-trial","Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC) - protocol for a randomised controlled trial","","A theory-driven randomized controlled trial protocol evaluates electronic patient-reported outcome (ePROs)-based symptom monitoring for hepatocellular carcinoma patients receiving immunotherapy in China. About 238 patients will be randomized 1:1 to an 18-week weekly WeChat platform intervention with reactive alerts and self-management advice or usual care. The primary endpoint compares HRQoL between groups at 18 weeks, with secondary clinical, mental health, and healthcare utilisation outcomes. Implementation outcomes include acceptability, feasibility, fidelity, and cost-effectiveness.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/electronic-symptom-monitoring-of-patient-reported-outcomes-among-patients-with-hepatocellular-carcinoma-during-immunotherapy-prime-hcc-protocol-for-a-randomised-controlled-trial/356807/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/electronic-symptom-monitoring-of-patient-reported-outcomes-among-patients-with-hepatocellular-carcinoma-during-immunotherapy-prime-hcc-protocol-for-a-randomised-controlled-trial/356807.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the PRIME-HCC trial protocol studying?","Question",{"text":113,"@type":114},"The protocol studies the clinical and implementation outcomes of ePROs-based electronic symptom monitoring for patients with hepatocellular carcinoma receiving immunotherapy in China.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are participants assigned and what does the intervention include?",{"text":118,"@type":114},"Approximately 238 participants will be randomized 1:1 to an intervention or control group. The intervention group completes an 18-week weekly ePROs symptom monitoring survey via a WeChat-based platform with reactive alerts and automated self-management advice.",{"name":120,"@type":111,"acceptedAnswer":121},"What outcomes does the study measure?",{"text":122,"@type":114},"Primary outcome is the between-group difference in HRQoL at 18 weeks. Secondary outcomes include physical function, symptom burden, overall survival, mental health, and healthcare utilisation, with implementation outcomes covering acceptability, feasibility, fidelity, and cost-effectiveness.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356807,1790472365,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Open access Protocol  \nTo cite: Xia Y, Wei X, Wang Y, et al. Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial. BMJ Open 2026;16:e116199 . doi:10 . 1136/ bmjopen-2026-116199  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2026-116199](bmjopen-2026-116199))  \nReceived 01 January 2026 Accepted 16 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Ping He; [phe@pku.edu.cn](phe@pku.edu.cn)  \nElectronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised  \ncontrolled trial  \nYiqi Xia,1,2 Xiaoping Wei,1,2 Yanshang Wang,3 Zhenyu Shi,4 Ping He  1,5,6,7  \nABSTRACT  \nIntroduction Electronic patient-reported outcome (ePROs)-based symptom monitoring benefits healthrelated quality of life (HRQoL) in various cancers.  \nHowever, despite the high disease and economic burden of hepatocellular carcinoma (HCC) and the complex symptom profile during immunotherapy, the effectiveness and implementation of ePROs-based interventions in this population remain unclear. This study aims to evaluate the clinical and implementation outcomes of ePROs-based symptom monitoring among patients with HCC receiving immunotherapy in China.  \nMethods and analysis The trial is a two-arm randomised controlled trial (RCT) . Approximately 238 patients with HCC undergoing immunotherapy in China will be recruited and randomly assigned (1:1) to an intervention or control group. The intervention group will receive an 18 week, weekly ePROs symptom monitoring survey via a WeChat-based platform, featuring reactive alerts that provide patients with automated, evidence-based self-management advice when predefined thresholds are exceeded. The control group will receive usual care. Guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) Framework and normalisation process theory (NPT), the study employs a mixed-methods approach. The primary outcome is the between-group difference in HRQoL at  \n18 weeks. Secondary effectiveness outcomes include physical function, symptom burden, overall survival, mental health and healthcare utilisation. Key implementation outcomes, assessed quantitatively and qualitatively, include acceptability, feasibility, fidelity, cost-effectiveness and the contextual mechanisms influencing sustainability and scalability.  \nEthics and dissemination The study has been approved by the Institutional Review Board of Peking University (IRB No. 00001052-24066) . This protocol is based on V2 .0, 6 July 2024 of the protocol. Electronic informed consent is obtained from all participants. Findings will be disseminated through peer-reviewed publications and academic conferences, providing evidence to inform scalable integration of digital symptom monitoring into oncology care.  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ This study is a theory-driven randomised controlled trial integrating Reach, Effectiveness, Adoption, Implementation, Maintenance Frameworks, implementation facilitation and health economic evaluation.  \n⇒ The trial uses a disease-specific symptom monitoring survey tailored to hepatocellular carcinoma patients receiving immunotherapy.  \n⇒ This trial innovatively combines digital intervention with behavioural nudges.  \n⇒ The study’s generalisability is limited by site heterogeneity, digital literacy variation and restrictive eligibility criteria.  \n⇒ The study uses the self-reported outcomes to evaluate effectiveness and cost","cbCaiksdHZDBQ072","https://ap.wps.com/l/cbCaiksdHZDBQ072","pdf",2130798,"English","# Abstract\n# Introduction\n# Methods and analysis\n# Ethics and dissemination\n# Strengths and limitations","[{\"question\":\"What is the PRIME-HCC trial protocol studying?\",\"answer\":\"The protocol studies the clinical and implementation outcomes of ePROs-based electronic symptom monitoring for patients with hepatocellular carcinoma receiving immunotherapy in China.\"},{\"question\":\"How are participants assigned and what does the intervention include?\",\"answer\":\"Approximately 238 participants will be randomized 1:1 to an intervention or control group. The intervention group completes an 18-week weekly ePROs symptom monitoring survey via a WeChat-based platform with reactive alerts and automated self-management advice.\"},{\"question\":\"What outcomes does the study measure?\",\"answer\":\"Primary outcome is the between-group difference in HRQoL at 18 weeks. Secondary outcomes include physical function, symptom burden, overall survival, mental health, and healthcare utilisation, with implementation outcomes covering acceptability, feasibility, fidelity, and cost-effectiveness.\"}]","Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC) - protocol for a randomised controlled trial | PDF",1790127406,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/911fcfcec57cfeb5b5e9f51bbe306a1f.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/762535c2fd79fcf7098214d260e9bd2b.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4da29c1032d35d46211f96b584c2dcdb.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de0aadd9b1152d091b76e17a7eed9a7d.webp",980,1306]